after effects of shingles vaccine injection

Zostavax was shown to reduce the incidence of shingles by 51% in a study of 38,000 adults aged 60 and older who received the vaccine. The need for re-vaccination remains to be confirmed. The duration of protection beyond four years after vaccination with the zoster vaccine is unknown. Ī Cochrane review concluded that Zostavax is 'effective in preventing herpes zoster disease for up to three years'. Īnother vaccine, known as varicella vaccine, is used to prevent diseases caused by the same virus. Shingrix appears to prevent more cases of shingles than Zostavax, although side effects seem to be more frequent. Zostavax was discontinued in the United States in November 2020. Unlike Shingrix, Zostavax is not suitable for people with immunosuppression or diseases that affect the immune system. Zostavax ( Merck), in use since 2006, is an attenuated vaccine which consists of a larger-than-normal dose of chickenpox vaccine. Shingrix ( GSK) is a recombinant subunit vaccine which has been used in many countries since 2017. Two zoster vaccines have been approved for use in people over 50 years old. Both shingles and postherpetic neuralgia can be prevented by vaccination. Older people are more often affected, as are people with weakened immune systems ( immunosuppression). Shingles provokes a painful rash with blisters, and can be followed by chronic pain ( postherpetic neuralgia), as well as other complications. A zoster vaccine is a vaccine that reduces the incidence of herpes zoster (shingles), a disease caused by reactivation of the varicella zoster virus, which is also responsible for chickenpox.

After effects of shingles vaccine injection